ID   Hs 834.T
AC   CVCL_0938
SY   Hs-834-T; Hs834T; HS834T
DR   CLO; CLO_0004145
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-7568
DR   BioSample; SAMN03471245
DR   BioSample; SAMN10988445
DR   Cell_Model_Passport; SIDM01709
DR   DepMap; ACH-000275
DR   GEO; GSM827550
DR   IARC_TP53; 30066
DR   LiGeA; CCLE_656
DR   PharmacoDB; Hs834_T_600_2019
DR   Progenetix; CVCL_0938
DR   Wikidata; Q54896100
RX   DOI=10.1101/166199;
RX   PubMed=20215515;
RX   PubMed=31068700;
CC   Problematic cell line: Misclassified. Originally thought to be a melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: ATCC; CRL-7568; true.
CC   Derived from sampling site: Cervical lymph node. Cell type=Fibroblast.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,12
ST   D16S539: 9,11
ST   D5S818: 11
ST   D7S820: 9,10
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   27Y
CA   Undefined cell line type
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 20
//
RX   DOI=10.1101/166199;
RA   de Weck A., Bitter H., Kauffmann A.;
RT   "Fibroblasts cell lines misclassified as cancer cell lines.";
RL   bioRxiv 2017:166199-166199(2017).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//